-
Phase 1 results announced for Skyhawk’s drug SKY-0515
Latest News
-
Re-routing the huntingtin protein inside cells
Canadian team decodes the tags that re-route the huntingtin protein within cells, helping explain how it becomes toxi
-
Not all in your head: digestive problems in HD
Huntington's disease mice absorb less nutrition from food – which might help explain why human patients lose weight.
-
Huntexil update: EMA asks for further trial
European Medicines Agency (EMA) tells NeuroSearch a European license for Huntexil in HD requires another large trial
-
KMO inhibitor drug improves lifespan of Huntington's disease mice
Positive results from tests of a new 'KMO inhibiting' drug in Huntington's disease mice
-
Meet the enemy: neutron ray reveals HD protein structure
Scientists use beams of neutrons to study the structure of clumps of mutant huntingtin protein
-
'Floating' gene-silencing drugs into the brain with exosomes
Exosomes – tiny bubbles made by cells – could be used to get gene silencing drugs from the bloodstream into the brain
-
Improving Huntington's disease clinical trial recruitment through patient and family education
How can we improve recruitment into Huntington's disease clinical trials? Talking directly with families works!
-
Chubby mice reveal the importance of the hypothalamus in Huntington's disease
Huntington's disease mice are fat but HD patients lose weight – is a brain area called the hypothalamus to blame?
-
The genetic 'gray area' of Huntington's disease: what does it all mean?
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-
Dimebon fails in late-stage human HD clinical trial
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
